CANbridge Life Sciences

Bio-pharmaceutical company accelerating development and commercialization of specialty healthcare.

Launch date

2012

Employees

Market cap

Enterprise valuation

$490m (Public information from Dec 2020)

Cambridge Massachusetts (HQ)

Date	Investors	Amount	Round
-	TF Capital	N/A	-
Dec 2014	Qiming Venture Partners	$10.0m	Series A
Oct 2015	Qiming Venture Partners	$10.0m	Series A
May 2017	WuXi AppTec Qiming Venture Partners YuanMing Capital Lapam Capital	$25.0m	Series B
Aug 2018	Qiming Venture Partners	$38.1m	Series C
Feb 2020*	General Atlantic Tigermed Hudson Bay Capital Management RA Capital Management YuanMing Capital Hangzhou Tigermed	$98.0m	Series D
Dec 2020	Tigermed Hudson Bay Capital Management Casdin Capital 3W Partners RA Capital Management LYFE Capital SPDB International Summer Capital Yaly Capital Hangzhou Tigermed & 1 more	$43.0m Valuation: $490m	Series E
Dec 2021*	N/A	$77.0m	IPO
Total Funding		$224m

Tech stackLearn more about the technologies and tools that this company uses.

Recent News about CANbridge Life Sciences